摘要:
This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.
摘要:
Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.
摘要:
This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.
摘要:
The present invention relates to the sequential administration of a cytotoxic agent followed by an IGF1R antagonist (e.g., an antibody) for the treatment of hyperproliferative disorders including cancer.
摘要:
The present invention provides, for example, methods for treating or preventing colorectal cancer with an anti-IGF1R antibody in association with sunitinib or a combination of leucovorin and 5-fluorouracil.
摘要:
The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.
摘要:
The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.
摘要:
The present invention provides formulations, kits and methods useful for treating cell proliferative disorder. In particular, the formulations, kits and methods include temozolomide (TMZ) in combination with a multi-targeted kinase inhibitor.
摘要:
The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.